Skip to content

Imunon, Inc.: 10-Q filed 2023-11-14

What Imunon, Inc. reported in its quarterly report filed 2023-11-14 (fiscal Q3 2023): 39 published measures, 106 facts as tagged in accession 0001493152-23-040803.

This filing

Form
10-Q (quarterly report)
Filed
2023-11-14
Fiscal period
fiscal Q3 2023
Accession
0001493152-23-040803 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Imunon, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-09-3024,654,428USD
At 2022-12-3143,975,894USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-09-306,582,686USD
At 2022-12-3114,648,028USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-09-3018,071,742USD
At 2023-06-3021,515,140USD
At 2022-12-3129,327,866USD
At 2022-09-3041,351,075USD
At 2022-06-3047,042,493USD
At 2021-12-3155,795,931USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-09-3012,884,199USD
At 2022-12-3111,492,841USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-3,476,614USD92
2023-01-01 to 2023-09-30-14,626,844USD273
2022-07-01 to 2022-09-30-6,148,290USD92
2022-01-01 to 2022-09-30-22,665,559USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-15,249,883USD273
2022-01-01 to 2022-09-30-18,089,337USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-01-01 to 2023-09-30451,759USD273
2022-01-01 to 2022-09-30222,891USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2022-07-01 to 2022-09-30125,000USD92
2022-01-01 to 2022-09-30375,000USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-3,668,810USD273
2022-01-01 to 2022-09-306,275,346USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-09-3014,310,051USD273
2022-01-01 to 2022-09-3019,165,809USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-09-30-383,294,669USD
At 2022-12-31-368,667,825USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-07-01 to 2023-09-309,376,872shares92
2023-01-01 to 2023-09-308,926,114shares273
2022-07-01 to 2022-09-307,098,741shares92
2022-01-01 to 2022-09-306,621,925shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-07-01 to 2023-09-309,376,872shares92
2023-01-01 to 2023-09-308,926,114shares273
2022-07-01 to 2022-09-307,098,741shares92
2022-01-01 to 2022-09-306,621,925shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-0.37USD/shares92
2023-01-01 to 2023-09-30-1.64USD/shares273
2022-07-01 to 2022-09-30-0.87USD/shares92
2022-01-01 to 2022-09-30-3.42USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-0.37USD/shares92
2023-01-01 to 2023-09-30-1.64USD/shares273
2022-07-01 to 2022-09-30-0.87USD/shares92
2022-01-01 to 2022-09-30-3.42USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-09-30823,551USD
At 2022-12-31548,301USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-09-30625,589USD273
2022-01-01 to 2022-09-301,962,807USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-3,904,068USD92
2023-01-01 to 2023-09-30-15,062,803USD273
2022-07-01 to 2022-09-30-6,174,566USD92
2022-01-01 to 2022-09-30-17,994,814USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-09-3021,725,452USD
At 2022-12-3136,779,691USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-01-01 to 2023-09-30197,080USD273
2022-07-01 to 2022-09-30127,025USD92
2022-01-01 to 2022-09-304,878,306USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-09-305,316,510USD
At 2022-12-3110,037,082USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-07-01 to 2023-09-303,904,068USD92
2023-01-01 to 2023-09-3015,062,803USD273
2022-07-01 to 2022-09-306,299,566USD92
2022-01-01 to 2022-09-3018,369,814USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-07-01 to 2023-09-301,980,693USD92
2023-01-01 to 2023-09-307,734,897USD273
2022-07-01 to 2022-09-302,408,680USD92
2022-01-01 to 2022-09-308,730,395USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-09-309,367,907shares
At 2022-12-317,436,197shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-09-3012,884,199USD
At 2022-12-3117,492,841USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-09-30401,337,485USD
At 2022-12-31397,980,023USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-09-3020,435USD
At 2022-12-3126,494USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-09-301,663,985USD
At 2022-12-31155,876USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-09-301,736,789USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-09-302,105,425USD
At 2022-12-316,647,902USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-09-303,019,135USD
At 2022-12-314,794,936USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-3,618,224USD92
2023-01-01 to 2023-09-30-14,632,903USD273
2022-07-01 to 2022-09-30-6,103,680USD92
2022-01-01 to 2022-09-30-22,683,009USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-301,923,375USD92
2023-01-01 to 2023-09-307,327,906USD273
2022-07-01 to 2022-09-303,890,886USD92
2022-01-01 to 2022-09-309,639,419USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-01-01 to 2023-09-30176,509USD273
2022-01-01 to 2022-09-30117,371USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-07-01 to 2023-09-30427,454USD92
2023-01-01 to 2023-09-30435,959USD273
2022-07-01 to 2022-09-3026,276USD92
2022-01-01 to 2022-09-30-4,670,745USD273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2023-01-01 to 2023-09-301,567,026USD273
2022-01-01 to 2022-09-301,383,446USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-09-30179,542USD273
2022-01-01 to 2022-09-304,742,734USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-09-302,751,190USD273
2022-01-01 to 2022-09-306,275,346USD273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2023-07-01 to 2023-09-30162,808USD92
2023-01-01 to 2023-09-30489,993USD273
2022-07-01 to 2022-09-30150,774USD92
2022-01-01 to 2022-09-30450,721USD273

Inspect the source

Entity
Imunon, Inc. / CIK 0000749647
Captured
2026-09-19T15:01:50.763Z
SEC response SHA-256
cf2e46071525a607b4d539753f5129368297f1e667d6fa4f8829e76132e7a85a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000749647.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))